Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. Conference Call to be Held Wednesday, August 1, 2012 at 11:00 a.m. Eastern...
HOPKINTON, Mass., May 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; Alseres) announced today that effective on Friday, May 8, 2009 trading in its shares on the NASDAQ...
HOPKINTON, Mass., April 30 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; the Company) announced today that on April 24, 2009 it entered into an Amendment to License...
HOPKINTON, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that on January 8, 2009, it received notice from the NASDAQ Stock Market ("NASDAQ") that for the...
HOPKINTON, Mass., June 8 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSINASDAQ:andNASDAQ:ALSE) today announced that its proposed name change to Alseres Pharmaceuticals, Inc...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.005 | 0.005 | 0.005 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.005 | 0.005 | 0.005 | 0 | 0 | CS |
| 156 | -0.005 | -50 | 0.01 | 0.01 | 0.005 | 11 | 0.00797546 | CS |
| 260 | -9.995 | -99.95 | 10 | 10 | 0.005 | 15 | 4.62238859 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| HCMCHealthier Choices Management Corporation (PK) | US$ 0,000001 (0,00%) | 316,07M |
| HMBLHUMBL Inc (PK) | US$ 0,0007 (0,00%) | 218,85M |
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0,00015 (-25,00%) | 210,68M |
| RONNRonn Motor Group Inc (PK) | US$ 0,0003 (0,00%) | 171,31M |
| AITXArtificial Intelligence Technology Solutions Inc (PK) | US$ 0,00275 (-1,79%) | 134,31M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
